Zobrazeno 1 - 10
of 1 280
pro vyhledávání: '"Non squamous"'
Autor:
Yanjuan Xiong, Lu Wang, Weihong Zhang, Yuan Meng, Yang Wang, Meng Shen, Li Zhou, Runmei Li, Yingge Lv, Shengguang Wang, Xiubao Ren, Liang Liu
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background The safety and efficacy of combination of gefitinib with chemotherapy and bevacizumab in treatment patients with epidermal growth factor receptor (EGFR) mutations are currently unknown. This study was designed to evaluate the safe
Externí odkaz:
https://doaj.org/article/b0881b39702747e19b426a096714747e
Autor:
Naoya Nishioka, Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Taishi Harada, Koji Date, Yusuke Chihara, Isao Hasegawa, Nobuyo Tamiya, Taiki Masui, Natsuki Sai, Masaki Ishida, Yuki Katayama, Kenji Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takashi Kijima, Koichi Takayama
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionSeveral studies explored the association between thyroid transcription factor-1 (TTF-1) and the therapeutic efficacy of immunotherapy. However, the effect of TTF-1 on the therapeutic efficacy of programmed death-1 (PD-1) inhibitor/chemoim
Externí odkaz:
https://doaj.org/article/b283d63fa0724718827e2777a8b09bb4
Autor:
Da Zhao, Zhengguo Li, Xinli Hou, Lei Yang, Zeng Li, Li Yan, Hongling Li, Hua Liu, Xiaoping Liu, Feixue Song, Guixiang Li, Yu Zhang, Xiaoming Hou
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundBased on pharmacoeconomics, drug availability and actual treatment, optimal treatment regimens for Chinese non-small-cell lung carcinoma (NSCLC) patients over 70 years old are needed.MethodsThis multicenter, single-arm pilot trial enrolled
Externí odkaz:
https://doaj.org/article/d59dd34bbefb4c36917d3dfcff8e1fa6
Autor:
Hye Ryun Kim, Shunichi Sugawara, Jong‐Seok Lee, Jin‐Hyoung Kang, Naoki Inui, Toyoaki Hida, Ki Hyeong Lee, Tatsuya Yoshida, Hiroshi Tanaka, Cheng‐Ta Yang, Makoto Nishio, Yuichiro Ohe, Tomohide Tamura, Nobuyuki Yamamoto, Chong‐Jen Yu, Hiroaki Akamatsu, Shigeru Takahashi, Kazuhiko Nakagawa
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 17061-17067 (2023)
Abstract Background ONO‐4538‐52/TASUKI‐52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for the initial (first‐lin
Externí odkaz:
https://doaj.org/article/b0fcd685eeec41798eee2fd83380a4ba
Autor:
Takashi Kasai, Kiyoshi Mori, Yoichi Nakamura, Nobuhiko Seki, Yasuko Ichikawa, Haruhiro Saito, Tetsuro Kondo, Kazuo Nishikawa, Satoshi Otsu, Akihiro Bessho, Hiroshi Tanaka, Hiroyuki Yamaguchi, Takayuki Kaburagi, Hisao Imai, Keita Mori, Junya Ohtake, Hiroaki Okamoto
Publikováno v:
Cancer Medicine, Vol 12, Iss 14, Pp 14988-14999 (2023)
Abstract Introduction Cisplatin plus pemetrexed followed by pemetrexed is an efficacious platinum combination regimen for advanced non‐squamous, non‐small cell lung cancer (NSCLC). Data regarding the addition of bevacizumab, especially in mainten
Externí odkaz:
https://doaj.org/article/eba439d047e748209a1bb12b174b1fd1
Publikováno v:
Cancer Medicine, Vol 12, Iss 12, Pp 13123-13134 (2023)
Abstract Purpose The relationship between mutant KRAS and the risk of disease progression and death in advanced non‐squamous non‐small cell lung cancer (NSCLC) is still controversial among current studies, and the effects of distinct KRAS mutatio
Externí odkaz:
https://doaj.org/article/d71fba77233848f28d7d1af41d0e7980
Publikováno v:
Annals of Medicine, Vol 55, Iss 2 (2023)
AbstractBackground This study aimed to compare the efficacy and safety of different treatment modalities for previously untreated advanced EGFR-mutated non-squamous non-small-cell lung cancer (NSCLC).Methods This retrospective study included 196 adva
Externí odkaz:
https://doaj.org/article/c8e4c4a6444c472a993f789090db0ad9
Autor:
Mohamed Said Ismail, Loay Kassem, Ahmed Al-Husseiny Ali, Fatma Elzahraa Ahmed, Mohamed Shalaby, Sally Magdy
Publikováno v:
Journal of the Egyptian National Cancer Institute, Vol 35, Iss 1, Pp 1-7 (2023)
Abstract Background Driver molecular aberrations, such as epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) gene rearrangement, play an important role in the oncogenesis and progression of non-squamous non-small-ce
Externí odkaz:
https://doaj.org/article/36f0297b96674b8ca5293d9ff9ec7526
Autor:
Tadashi Nishimura, Takumi Fujiwara, Hajime Fujimoto, Hirotoshi Tarumi, Chikashi Tsuji, Soichi Iwanaka, Yasumasa Sakakura, Masahiro Naito, Yoshinaga Okugawa, Taro Yasuma, Esteban Cesar Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Hidenori Ibata
Publikováno v:
Thoracic Cancer, Vol 14, Iss 7, Pp 709-713 (2023)
Abstract Epidermal growth factor receptor (EGFR)‐mutated squamous cell carcinoma (SCC) is less common than adenocarcinoma. The third‐generation EGFR‐tyrosine kinase inhibitor, osimertinib, is effective in EGFR‐mutated lung adenocarcinoma, but
Externí odkaz:
https://doaj.org/article/9ea80970dd944d21ac84afcf94028e19
Publikováno v:
Discover Oncology, Vol 13, Iss 1, Pp 1-11 (2022)
Abstract Non-small cell lung cancer (NSCLC) is one of the most malignant tumors. The study was carried out to investigate the prognostic value of Beclin 1, EGFR and ALK for this cancer. Patients diagnosed with non-squamous NSCLC and admitted to our h
Externí odkaz:
https://doaj.org/article/0a599fa1a2bd4a9090cbd322dcc7e977